You Are Leaving the Medtronic Indian Subcontinent Site

You just clicked a link to go to another website. If you continue, you will leave this site and go to a site run by someone else.

Medtronic does not review or control the content on the other website, and we are not responsible for any business dealings or transactions you have there. Your use of the other site is subject to the terms of use and privacy statement on that site.

It is possible that some of the products on the other site are not approved in the Indian Subcontinent.

Any and all information provided is intended for general overview. Viewers taking any decision based on the information provided herein are requested to seek professional advice.

Research and Development at India Medtronic

Research and Development (R&D) is aligned with our mission, focused on addressing universal healthcare needs, improving clinical outcomes, expanding global access to care and optimizing costs and efficiencies across the healthcare continuum—through three core strategies: Therapy innovation, Globalization and Economic Value.

Medtronic has been leveraging the unique strength of India beyond providing therapies to the patients in India. To take advantage of India’s strength with a large pool of qualified engineers, doctors with wide ranging patient pool experience & hospitals providing quality care, Medtronic established-

Medtronic Engineering and Innovation Centre, Hyderabad(MEIC) – a state of the art, IT-enabled, captive engineering R&D center in India. It provides high-quality, high-performance, cost-effective engineering services to Medtronic’s products and its global and regional business units, supporting their product development and other engineering functions.

Medtronic India Development Centre, Bangalore (MIDC) - The center focuses on key product, design and development aspects of the Renal Care Solutions business, which is currently developing a new hemodialysis system. MIDC aims to address the barriers that prevent wider availability of therapy for patients with end stage renal disease in emerging countries such as India.